India, Oct. 16 -- Venus Remedies Ltd has obtained five marketing authorisations across Kazakhstan, Peru, Kuwait and Argentina, expanding its international presence and strengthening access to its pharmaceutical products in key overseas markets.
The approvals cover Vancomycin and Fluorouracil in Kazakhstan, Fulvestrant in Peru, Methotrexate in Kuwait and Meropenem in Argentina. The authorisations extend across the Commonwealth of Independent States (CIS), Latin America and the Middle East.
Saransh Chaudhary, Executive Director of Venus Remedies and CEO of Venus Medicine Research Centre (VMRC), said the approvals represent another step towards expanding the company's global footprint and broadening its product reach across international mar...